Status:
TERMINATED
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Lead Sponsor:
Novartis
Conditions:
Opioid-induced Constipation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation (OIC) in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF919N220...
Eligibility Criteria
Inclusion
- Patient has completed the 12 week double blind treatment of study CHTF919N2201
Exclusion
- Planned discontinuation of opioids during the study.
- Development of any of the medical conditions listed as exclusion criteria for the CHTF919N2201 study.
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT00399659
Start Date
November 1 2006
End Date
April 1 2007
Last Update
May 1 2012
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Mobile, Alabama, United States, 36608
2
Investigative Site
Phoenix, Arizona, United States, 85029
3
Investigative Site
Phoenix, Arizona, United States, 85050
4
Investigative Site
Tucson, Arizona, United States, 85712